January 21, 2021 - 4:09am EST by
2021 2022
Price: 3.69 EPS 0 0
Shares Out. (in M): 104 P/E 0 0
Market Cap (in $M): 371 P/FCF 0 0
Net Debt (in $M): -140 EBIT 0 0
TEV (in $M): 231 TEV/EBIT 0 0

Sign up for free guest access to view investment idea with a 45 days delay.


I do not hold a position with the issuer such as employment, directorship, or consultancy.
I and/or others I advise hold a material investment in the issuer's securities.


The most obvious catalyst for CPRX is a return to patient growth as COVID subsides. Other triggers may be 1) an acquisition by the company that increases earnings putting it on the radar of more analysts, 2) approval for their drug in Japan which is a large market, or 3) approval for the use of Firdapse to treat another disease. The last trigger, which would obviously be a hallelujah outcome, is that CPRX are acquired by a large pharmaceutical company that wants to bolster their rare disease drug portfolio - CPRX is a very digestible size with a market cap of $370m.

    show   sort by    
      Back to top